No Data
No Data
Theratechnologies Shareholders Elect Directors, Appoint Auditors
Theratechnologies Elects New Board Chair
Theratechnologies Reports on Its Annual Meeting of Shareholders
MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (Sudocetaxel Zendusortide) in Solid Tumors at 2024 ASCO Meeting
First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid tumors Part 3 of Phase 1 trial in advanced ovarian cancer is ongoing MONTREAL, May 02, 2024
Theratechnologies Announces Virtual Annual Meeting
Theratechnologies Announces Mailing of Management Proxy Circular in Connection With Its Annual Meeting of Shareholders
No Data